NorthWest Biotherapeutics Inc (NWBO)

[Horseb4CarT]

When one has the secret sauce that either enables or enhances the efficacy of N checkpoint inhibitors/pd1/PDL1 of a blockbuster nature, and possibly other combo adjuvant candidates what can you do?

Either you play kingmaker with one perhaps of each type of adjuvant, foregoing the other N-1 candidates and their potential combo sales (and becoming a target for legal and antitrust attacks)

Or

Set up for multiple partnerships and thus enable the most parallel advancements and relationships, accomplishing more for advancing the fight across different cancers, encouraging the competition among the combo candidates to trial and improve the efficacy of their combo treatments, and transforming nwbo (or resulting entity owning the DCVax platform) from a target to be destroyed into a necessary partner that enables a candidate combo to succeed and incentivizing each partner to be at least as good or better than the competitors for an indication.

So, imo creating some type of multiple partnerships and/or licensing arrangement would be in our and the industry’s and especially the patients best interests. I think this would remove DCVax from being an endangered species, at least until some better breakthrough should be discovered.

Of course since the skeleton crew (and mature ones) at nwbo is presently not staffed to do the heavy lifting, the arrangement needs to address that either by allocation of responsibilities and costs, or by the surviving DCVax platform entity structurally adapting.